Drug Profile
Dapagliflozin/olmesartan medoxomil - Autotelic Bio
Alternative Names: ATB-101; ATB-1011/ATB-1012; ATB-1012/ATB-1011Latest Information Update: 27 Oct 2022
Price :
$50
*
At a glance
- Originator Autotelic Bio
- Class Antihyperglycaemics; Antihypertensives; Benzhydryl compounds; Chlorobenzenes; Eye disorder therapies; Glucosides; Heart failure therapies; Imidazoles; Obesity therapies; Pyrans; Small molecules; Tetrazoles; Urologics
- Mechanism of Action Angiotensin type 1 receptor antagonists; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Diabetes mellitus; Hypertension
Most Recent Events
- 17 Oct 2022 Phase-III clinical trials in Diabetes mellitus in South Korea (PO) (NCT05573477)
- 17 Oct 2022 Phase-III clinical trials in Hypertension in South Korea (PO) (NCT05573477)
- 12 Oct 2022 Autotelic Bio plans a phase III trial for Essential Hypertension and Type 2 diabetes mellitus in South Korea (PO) in October 2022(NCT05573477)